Lee’s Pharmaceutical Holdings Ltd. (“Lee’s Pharm” or “the Company”; Hong Kong stock code: 0950.HK), a research-based biopharmaceutical company, is pleased to announce that a wholly owned subsidiary of its associated company, Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Ltd (“ZKO”) has recently entered into an exclusive licensing agreement with Nevakar Inc. (“Nevakar”), a US-based privately held, late-stage, biopharmaceutical company developing multiple innovative medications in the ophthalmic and hospital injectable areasfor the development and commercialization of NVK-002 in Greater China (The People’s Republic of China (“PRC”), Hong Kong SAR, Macau SAR and Taiwan), South Korea and the Southeast Asian territories1. NVK-002 is a preservative-free, novel topical eye treatment for slowing the progression of myopia in children and is currently in a Phase 3 clinical trial study (“Childhood Atropine for Myopia Progression” or “CHAMP“ study) in the US and Europe.
Thai 
English